<DOC>
	<DOCNO>NCT02446015</DOCNO>
	<brief_summary>The purpose study evaluate clinical benefit SYSTANE速 ULTRA Lubricant Eye Drops use total ocular surface stain score subject dry eye administer either scheduled regimen as-needed 28 day treatment . This study conduct US Australia .</brief_summary>
	<brief_title>Clinical Evaluation Following Use SYSTANE速 ULTRA Management Dry Eye</brief_title>
	<detailed_description>This study consist 14-day Run-in Phase ( Screening Visit Baseline/Visit 1 ) Treatment Phase . During Run-in Phase , subject discontinue current artificial tear dispense SYSTANE速 ULTRA administer 1 drop eye need ( PRN ) . Subjects meet re-evaluation criterion Run-in Phase randomize 1:2 manner receive treatment SYSTANE速 ULTRA 4 time per day ( QID ) PRN , respectively , 28 day .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<criteria>Willing able attend study visit . Use BAKfree artificial tear drop need basis , least week , within 3 month prior Screening Visit ( maximum use 4 drop day ) . At least one ' 8 hour wake period ' per week runin phase without use provide artificial tear . Use provide artificial tear least week runin phase . Willing take study treatment direct entire study able complete study diary require . Other protocolspecified inclusion criterion may apply . Use artificial tear , specify protocol . Use topical ocular medication , specify protocol . Women childbearing potential pregnant , breast feeding , plan become pregnant study , use adequate birth control method prevent pregnancy throughout study . Any hypersensitivity use study product formulation allergy ingredient ( ) contain within product formulation . Ocular abnormality , infection , active inflammation ( associate dry eye ) specify protocol . Ocular intraocular surgery serious ocular trauma either eye within past 6 month prior Screening Visit . Any medical condition ( systemic ophthalmic ) may preclude safe administration test article safe participation study . Contact lens use within 2 week prior Screening Visit , unwilling avoid contact lens use course study . Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>